[Treatment of a patent duct in neonates].
A Jurko, E Hlaucová, Mark Fedor, Tilman Klein, A Jurko
Abstract
A Jurko, E Hlaucová, Mark Fedor, Tilman Klein, A Jurko
Abstract
The authors analyze clinical and laboratory aspects of Indomethacin treatment of neonates with a patent ductus arteriosus. From June 1987 to November 1990 the authors treated 19 neonates with a patent ductus arteriosus with Indomethacin. The drug was administered, 0.1-0.3 mg/kg body weight, by the oral route three times/24 or 36 hours. In 17 infants after Indomethacin treatment the duct closed, in two infants the duct did not close during Indomethacin treatment, in three infants the authors observed oliguria which improved after discontinuation of treatment.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The authors analyze clinical and laboratory aspects of Indomethacin treatment of neonates with a patent ductus arteriosus. From June 1987 to November 1990 the authors treated 19 neonates with a patent ductus arteriosus with Indomethacin. The drug was administered, 0.1-0.3 mg/kg body weight, by the oral route three times/24 or 36 hours. In 17 infants after Indomethacin treatment the duct closed, in two infants the duct did not close during Indomethacin treatment, in three infants the authors observed oliguria which improved after discontinuation of treatment.
Key concepts: Ductus arteriosus, Oliguria, Medicine, Discontinuation, Duct (anatomy), Anesthesia, Pediatrics, Surgery